A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients

International Journal of Clinical Practice

Volumn 62, Issue 2, 2008, Pages 314-324

  Henney III, H R ^a   Runyan, J D ^a  

^a ACORDA THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ESTRADIOL; FLUVOXAMINE; GESTODENE; ORAL CONTRACEPTIVE AGENT; PLACEBO; TIZANIDINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION COEFFICIENT; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; EYE FIXATION; HUMAN; HYPOTENSION; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SOMNOLENCE; SPASTICITY; URINE VOLUME; XEROSTOMIA;

CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUVOXAMINE; HUMANS; MULTIPLE SCLEROSIS; MUSCLE RELAXANTS, CENTRAL; TREATMENT OUTCOME;

EID: 38149038075     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01660.x     Document Type: Review

References (32)

1. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl 1997 6 : S1 13.
2. Haselkorn JK, Balsdon Richer C, Fry Welch D et al. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2005 28 : 167 99.
3. Sayers AC, Burki HR, Eichenberger E. The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent. Arzneimittelforschung 1980 30 : 793 803.
4. Mathias CJ, Luckitt J, Desai P et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev 1989 26 : 9 16.
5. Curtis DR, Leah JD, Peet MJ. Spinal interneurone depression by DS103-282. Br J Pharmacol 1983 79 : 9 11.
6. Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiodazole (DS103-282). Br J Pharmacol 1982 76 : 473 81.
7. Tanabe M, Kaneko T, Tonohiro T, Iwata N. The pharmacological properties of CS-722, a newly synthesized centrally acting muscle relaxant. Neuropharmacology 1992 31 : 1059 66.
8. Emre M, Leslie GC, Muir C et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry 1994 57 : 1355 9.
9. Hassan N, McLellan DL. Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity. J Neurol Neurosurg Psychiatry 1980 43 : 1132 6.
10. Knutsson E, Martensson A, Gransberg L. Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. J Neurol Sci 1982 53 : 187 204.
11. Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994 44 : S60 8.
12. Nomura M, Kusaba-Suzuki M, Kimura T et al. Cardiovascular effects of tizanidine, a new centrally acting muscle relaxant, in rats and dogs. Pharmacometrics 1985 29 : 477 91.
13. Ono H, Matsumoto K, Kato K et al. Effects of tizanidine, a centrally acting muscle relaxant, on motor systems. Gen Pharmacol 1986 17 : 137 42.
14. Skoog B. A comparison of the effects of two antispastic drugs, tizanidine and baclofen, on synaptic transmission from muscle spindle afferents to spinal interneurones in cats. Acta Physiol Scand 1996 156 : 81 90.
15. Taittonen M, Raty H, Kirvela O et al. The metabolic effects of oral tizanidine in healthy volunteers. Acta Anaesthesiol Scand 1995 39 : 628 32.
16. Venitz J. Using Exposure-Response Relationships to Define Therapeutic Index: a Proposed Approach Based on Utility Functions. http://www.fda.gov/ohrms/ dockets/ac/02/slides/3898S1_06_Venitz.pdf (accessed June 2007).
17. Gracies JM, Nance P, Elovic E et al. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl 1997 6 : S92 120.
18. Roberts RC, Part NJ, Pokorny R et al. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology 1994 44 (Suppl. 9 S29 31.
19. Hutchinson DR. Modified release tizanidine: a review. J Int Med Res 1989 17 : 565 73.
20. Tse FL, Jaffe JM, Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundam Clin Pharmacol 1987 1 : 479 88.
21. Koch P, Hirst DR, von Wartburg BR. Biological fate of sirdalud in animals and man. Xenobiotica 1989 19 : 1255 65.
22. Nance PW, Sheremata WA, Lynch SG et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997 54 : 731 6.
23. ® tablets [package insert]. Hawthorne, NY : Acorda Therapeutics, 2006.
24. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 2004 57 : 349 53.
25. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005 78 : 400 11.
26. Granfors MT, Backman JT, Neuvonen M et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 2004 75 : 331 41.
27. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004 76 : 598 606.
28. Backman JT, Karjalainen MJ, Neuvonen M et al. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 2006 62 : 345 57.
29. Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 2006 62 : 451 61.
30. Shah J, Wesnes KA, Kovelesky RA, Henney HR III. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clin Ther 2006 28 : 1308 17.
31. Henney HR III., Shah J. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. Clin Ther 2007 29 : 661 9.
32. Acorda Therapeutics. Data on File. Clinical Trial Report on: Protocol 400002; A Study in Healthy Volunteers to Evaluate the Relative Bioavailability of a Tizanidine IR Formulation when Administered in a Capsule and in a Sprinkle Form. Acorda Therapeutics, 2000, NDA 21-447.